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ABSTRACT 
Transdermal drug delivery is a noninvasive delivery method which can have 
numerous advantages for patients. It bypasses first-pass metabolism and can produce 
a constant and sustained delivery flux when compared to other drug delivery 
pathways (i.e. oral and injection). To effectively achieve those requirements, 
microemulsion (ME) formulations have been used as the drug delivery vehicles 
because they can form spontaneously, are thermodynamically stable and possess high 
solubilization capacity for drug compounds. This project optimized the composition 
of topical biocompatible ME formulations and evaluated their transdermal 
permeation capacity.  
In this study, medium chain monoglycerides (MCM) was found can act as the 
transdermal permeation enhancer in ME formulations. The transdermal permeation 
rate of sodium fluorescein (NaFlu) produced by both MCM alone and MCM 
incorporate with surfactant mixture (Tw/Sp) were significantly higher (over 30 and 
25-fold, respectively) than that produced by phosphate buffered saline (PBS). 
Additionally, increasing concentration of MCM leads to an increasing monophasic 
region (AT) from 15.2% to 33.2% of pseudo-ternary phase diagrams. When 
incorporated with MCM, it is observed that ethanol (EtOH) largely expanded the AT 
of pseudo-ternary phase diagrams to 52.3% and effectively improved the transdermal 
delivery rate of ME formulations. The transdermal delivery rate of different 
surfactants composed with MCM and EtOH based ME formulations was tested in 
vitro through hairless mice skin. Both ME formulation contained surfactant BRIJ 
O10 and Tween 80 presented great permeation performance (over 33 and 29-fold, 
respectively) when comparing with PBS in delivery of NaFlu. Besides, either 
surfactant BRIJ O10, Tween 80 or Kolliphor EL showed great results of gentamicin 
permeation performance (over 10, 13 and 14-fold, respectively) than in PBS when 
composed with MCM and EtOH based ME formulations. Therefore, ME formulation 
contains Tween 80 (ME_T8) was selected to assess the bio-distribution of 
gentamicin in vivo. Results showed that the gentamicin can’t go through mouse skin 
when dissolved in the PBS treatment. It is found that formulation ME_T8 did 
facilitate the transdermal delivery of gentamicin through mouse skin to produce 
detectable systemic drug levels. Furthermore, it is observed that the cumulative 
 
 
 
ii 
amounts of gentamicin in the kidney increasing 2.3-fold when double dose 
gentamicin was applied in comparison with the single dose ME treatment. 
These findings indicate monoglyceride-based MEs can act as transdermal drug 
delivery vehicles with tunable skin permeation characteristics. 
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1 INTRODUCTION 
1.1 Introduction of the skin 
1.1.1 Overview 
Skin is the largest organ of human body that also provides a series of functions 
essential for survival. It accounts for up to 16% of body weight with a total surface 
area of 1.8 m2. Skin provides physical protection from environmental challenges 
such as micro-organisms, ultraviolet radiation, toxic agents and mechanical insults 
but also functions by controlling the inward and outward passage of water, 
electrolytes and various substances. Since the out layer cells are continuously shed 
and replaced by inner layer cells moving up to the surface, this constant change 
contributes to the dynamic state of skin (Bensouilah and Buck, 2007).  
1.1.2 The structure of the skin 
The skin consists of three main layers (Fig 1.1): the epidermis, the dermis and 
subcutaneous tissue. The epidermis and dermis are considered as the key components 
of skin. The subcutaneous tissue is a layer of subcutaneous fat below them. 
 
Fig 1.1 Cross-section of skin (James et al., 2016). Three layers compose the skin 
structure: the epidermis, the dermis and subcutaneous tissue. 
1.1.2.1 The epidermis 
The epidermis is the external layer composed of layers of keratinocytes but also 
containing melanocytes, Langerhans cells and Merkel cells. It acts as the physical 
and chemical barrier between the interior body and exterior environment. There are 
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four separate layers of the epidermis: Horny cell layer (stratum corneum), granular 
cell layers (stratum granulosum), squamouse cell layer (stratum spinosum) and basal 
cell layer (stratum germinativum). These four layers are formed by the various stages 
of keratinocyte maturation (James et al., 2016, Lever and Elder, 2005). 
Basal Layer: The basal cell layer is the deepest layer of the epidermis. It lies close to 
the dermis and comprises mainly dividing and non-dividing keratinoctytes, which are 
attached to the basement membrane by hemidesmosomes. Keratinocytes move from 
this deeper layer to the surface and continually divide and differentiate. Below the 
basal cell layer are blood vessels in the dermis, which supply nutrients to facilitate 
this active growth of fresh skin cells. Basal cell will change their content and shape 
as they move away from this nutrient supply (Murphy, 1997). 
Squamous Layer: Above the basal layer there is the squamous layer which 
comprises irregular shaped cells that are initially formed by reproduction and 
maturity of basal cells (Murphy, 1997). These cells are connected by intercellular 
bridges and desmosomes. Langerhans cells that possess dendritic and immunological 
activity are found mainly in this area (Chu, 2008). 
Granular Layer: In the granular cell layer, cells display a flattened appearance, lose 
their nuclei and their cytoplasm appears granular. Keratin protein also accumulates in 
these cells (Chu, 2008). 
Horny Layer: The outermost layer of the epidermis is the stratum corneum and is 
the final outcome of keratinocyte maturation. This layer is made up of hexagonal-
shaped, non-viable cornified cells named corneocytes (Blank, 1953, Monash, 1958). 
Corneocytes are arranged in overlapping layers surrounded in stacked lipid bilayers 
that fill the extracellular space. This spatial arrangement produces a natural physical 
and waterproof character to the surface. Dead cells are continually sheded, from the 
skin surface which is balanced by the dividing cells moving up from the basal cell 
layer. In this layer, melanin is absorbed into the dividing skin cell to protect skin 
from ultraviolet light (Bensouilah and Buck, 2007). 
1.1.2.2 The dermis 
Below the epidermis is the dermis which ranges in thickness from 0.6 mm on the 
eyelids to 3 mm on the soles, back and palms. Two layers comprise the dermis. The 
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thin papillary layer has many ridges builds human beings individual fingerprints and 
comprises, thin loosely arranged collagen fibers whilst a thicker reticular layer 
extends from the base of the papillary layer to the subcutis tissue. Up to 70% of the 
dermis is made of collagen fibers which provide strength and toughness to skin. The 
remaining area is made up of elastin fibers, which give skin elasticity and flexibility, 
and proteoglycan which provides viscosity and hydration. Immune-competent mast 
cells and macrophages are also present within the dermis layer. Dermal vasculature, 
lymphatics, nervous cells and fibers, sweat glands, hair roots and small quantities of 
striated muscle are contained in the fibrous tissue of dermis and these structures 
contribute to for the various functions of the skin (Bensouilah and Buck, 2007). 
1.1.2.3 Subcutaneous fat 
The thickness of subcutaneous fat varies in different body regions. This fat layer is 
located in the deepest region of skin and helps reduce the harmful physical effects 
from the environment as well as acting as an energy resource (James et al., 2016). 
1.1.3 Skin barrier function 
The outmost layer of the epidermis is the stratum corneum which largely responsible 
skin barrier function. The stratum corneum was considered to be biologically inert 
before the mid-1970’s but in the past 30 years, the complicated biological and 
chemical properties of stratum corneum have been revealed. 
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Fig 1.2 The “brick and mortar” pattern of stratum corneum. The corneocyte is 
protein-based and hydrophobic lipids are extracellularly sequestered in the stratum 
corneum (Prausnitz et al., 2012). 
The structure of stratum corneum is commonly described with a ‘brick and mortar’ 
analogy (Fig 1.2). In this model, the corneocytes can be seen as complex 
proteinaceous bricks which are made of keratin fibers within an organized matrix. 
Depending on factors such as age, location and exposure to UV, the average 
thickness of each corneocyte is 1 micrometre. Generally, about 12 to 16 layers of 
corneocytes are contained in the stratum corneum  (Prausnitz et al., 2012). Within the 
stratum corneum, corneocytes are embedded in a lamellar lipid bilayer enriched in 
ceramides, cholesterol, and free fatty acids that are released by epidermal organelles 
known as lamellar bodies  (Elias and Menon, 1991). This lipid bilayer is considered 
as the ‘mortar’ in the brick and mortar model and has an important role maintaining 
the barrier property of skin. The hydrophobic layer of ceramide lipids adhering to the 
cornified cell envelope impede both the outward and inward movement of water 
producing a stable water balance (Prausnitz et al., 2012). 
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1.2 Topical Drug Delivery 
Topical drug delivery is defined as the application of a drug containing formulation 
to the skin. It is used to treat cutaneous disorders or the cutaneous manifestations of a 
general disease with the intent of containing the pharmacological or other effect of 
the drug to the surface of the skin or within the skin layers. 
1.2.1 Advantages and disadvantages 
The main advantage of topical delivery is to bypass first pass metabolism. 
Additionally, it is convenient and easy to apply and avoids the risks and 
inconveniences of systemic delivery methods. Topical delivery can also be a more 
efficient vehicle by supplying a consistent and continuous level of drug input that 
avoids the large drug fluctuations produced by oral and intravenous delivery methods 
(Paudel et al., 2010, Kumar et al., 2011). 
However, topical drug delivery may cause skin irritation, contact dermatitis or 
allergic reactions due to the drug and/or excipients present in the formulation. 
Additionally, the enzymatic activity present in epidermis can modify drug 
compounds reducing their activity. Furthermore, many drug compounds permeate the 
skin poorly therefore topical drug delivery is mainly used for drug compounds that 
require limited plasma concentration (Kumar et al., 2011). 
1.2.2 Transdermal drug delivery 
Topical drug application is used to produce effects at the site of application and 
doesn’t produce high drug concentrations in the blood and other tissues. Transdermal 
drug delivery refers to the process where drug compounds penetrate through the 
upper layers of skin and into deeper tissue or even to sites away from the application 
area. Drugs delivered transdermally can pass into the systemic circulation at a 
constant concentration, avoiding hepatic first pass metabolism enabling the 
application of lower dosages and the use of drug compounds with short biological 
half-life (Gaikwad, 2013). 
The primary pathway for the diffusion of drug compounds across skin is trans-
epidermal absorption. The biggest barrier to this process is the stratum corneum. The 
most common mechanism for diffusion through the stratum corneum is via the 
intercellular lipoid route (Flynn and Stewart, 1988). 
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Eccrine and sebaceous glands are appendages that can offer a secondary permeation 
pathway known as the trans-follicular or shunt pathway. Since eccrine and sebaceous 
glands are present all over the body, these avenues are regarded as shunts which 
bypass the stratum corneum. However, these pathways have limitations for 
percutaneous absorption. The orifices of these glands are small and make up a 
negligible amount of skin surface area. Furthermore, molecules cannot diffuse 
inwardly against the glands output since they are profusely active and constantly 
being evacuated. The opening of the follicular pore provides a more useful pathway 
for percutaneous absorption. The envisioned mechanism of permeation is 
partitioning into sebum, followed by diffusion through the sebum to the depths of the 
epidermis. Subsequent systemic entry is via the vasculature located in the dermis  
(Flynn and Stewart, 1988). 
1.2.3 Transdermal drug delivery methods 
Several methodologies can be used for transdermal drug delivery. They can be 
divided into physical or chemical methodologies (Table 1.1). However, transdermal 
delivery strategies may involve combinations of the various methodologies.  
Table 1.1 Transdermal drug delivery strategies 
Physical methods Chemical permeation enhancers 
Electroporation Solvents and organic acids 
Iontophoresis Polyols 
Microneedles Surfactants, fatty acids, fatty acids esters, 
Azone and its derivatives, amides, 
sulfoxides and terpenes 
Needle-free and ballistic injections 
Sonophoresis 
Photomechanical wave 
Magnetophoresis 
1.2.3.1 Physical Methods:  
Utilizing voltage gradients, electroporation and iontophoresis disrupt the SC to 
promote the permeation of large molecules like peptides through intact skin (Weaver 
et al., 1999). The local anesthetic compound lidocaine has been successfully 
delivered transdermally via iontophoresis (Sugar and Neumann, 1984). Some 
intravenous drugs are also available through iontophoresis (Turner et al., 1997). 
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However, these techniques require large machines, restricting their clinic availability 
(Huzil et al., 2011). 
Drugs can be transdermally delivered through the use of microneedles and high-
pressure needle-free injection. These methods facilitate transdermal drug delivery by 
bypassing the skin barrier through direct puncturing or abrasion of the SC (Burkoth 
et al., 1999). Additionally, ultrasonic and electromagnetic energy has been used for 
transdermal deliver via sonophoresis; and magnetophoresis respectively. Mechanical 
energy was utilized as photomechanical wave on the skin (Lee et al., 1999). However, 
these approaches are generally used as complementary methods and display limited 
transdermal delivery performance (Barry, 2001). 
1.2.3.2 Chemical permeation enhancers: 
Chemical permeation enhancers that reduce the barrier function of skin can also be 
used for transdermal drug delivery. There are 3 main groups of chemical permeation 
enhancers that are classified according to their mechanism of action. The 1st group of 
enhancers reduce skin barrier function by extracting the lipid layers of the SC, like 
solvents (e.g., ethanol) and organic acids (e.g., salicylic acid). The 2nd group of 
enhancers improve transdermal delivery by increasing the solubility of active 
compounds in the skin and include polyol compounds such as propylene glycol. The 
3rd group enhancers like terpenes, surfactants, fatty acids, fatty acid esters, Azone 
and its derivatives, amides and sulfoxides alter the intercellular lipid. Intercellular 
lipid phase fluidity is able to improve and its resistance can be limited after applying 
surfactants (Cócera et al., 1999, Shokri et al., 2001, Honeywell-Nguyen and 
Bouwstra, 2003). 
Chemical penetration enhancers acting within the skin should possess; low toxicity, 
low irritability and low allergenicity, rapid enhancement with activity and duration 
being both predictable and reproducible, no pharmacological activity within the body 
and should work unidirectional (i.e. therapeutic agents should be allowed into the 
body whilst preventing the loss of endogenous materials from the body) and should 
be cosmetically acceptable with an appropriate skin feel. Furthermore, skin barrier 
properties should return both rapidly and fully to normal when the penetration 
enhancers are removed (Huzil et al., 2011). Although some chemical enhancers 
possess a subset of the above attributes, currently no single enhancer possess all 
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these ideal properties. Chemical permeation enhancers were chosen to improve the 
topical drug applications in this study. 
1.3 Medium chain monoglycerides (MCM) as transdermal drug delivery 
enhancers 
1.3.1 Structures 
MCM are fatty acid monoesters of glycerol. Due to the orientation of that molecule, 
two isomeric forms exist (Fig 1.3). 
 
Fig 1.3 The chemical structure of MCM (Moonen and Bas, 2014). OCR is a 
saturated or an unsaturated hydrocarbon chain with 6 to 12 carbons in length. 
1.3.2 Transdermal permeation enhancers 
MCM can be formed by both industrial chemical and biological process. By 
diacylglycerol lipase, MCM are biochemically formed through the release of a fatty 
acid from diglycerides and can break down by monoglyceride lipase. Either animal 
or vegetable can be the commercial source, and may be synthetically made as well. 
Mono- and diglycerides are commonly added to food products in small quantities as 
emulsifiers and considered as GRAS compounds (Informatics, 1973). Commercial 
‘MCM’ were used in the cosmetic production which are mixture of MCM, 
diglyceirdes and triglycerides before 1969. Then the distilled monoester (94-96%) 
were manufactured for food and cosmetic formulation purpose (Kabara, 1991). The 
use of glycerides on medical purpose is already commercially available on US 
market. For example, transdermal glyceryl trinitrate patch was used to treat stoke 
topically and approved by FDA (Paudel et al., 2010). 
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1.3.3 MCM as transdermal permeation enhancers 
MCM have enhanced the transdermal permeation rate of numerous drug compounds. 
Glyceryl monocaprylate (C8) significantly improved the transdermal delivery rate of 
pentazocine compared with other permeation enhancers (i.e. isopropyl myristate 
solution alone, carboxylic acids, non-ionic surfactants, l-menthol, alcohols, glycol 
and urea) from isopropyl myristate solution system (IPM) (Furuishi et al., 2007). In 
this study, two derivatives of glyceryl monocaprylate (glyceryl diglycerides and 
glyceryl triglycerides) were proved have no permeation enhancement effect of 
pentazocine. It also investigated how fatty chain length derived from MCM affect the 
permeation rate of pentazocine (table 1.2). The flux reached the highest when 
glyceryl monocaproate (GEFA-C6) was tested, indicating that the suitable carbon 
number of glycerol ester of fatty acids is around six. Comparing glyceryl 
monocaprylate (GRFA-C8) and glyceryl monocaproate (GRFA-C6), the former is 
suitable as a permeation enhancer because of its safety and odorless properties.  
Table 1.2 Permeation rate (Flux) of pentazocine with various glycerol ester of fatty 
acids (GEFAs) (Furuishi et al., 2007) 
Enhancer Flux (g/cm2/h) 
IPM alone 
GEFA-C2 
14.4  0.8 
19.0  3.4 
GEFA-C4 37.5  6.4 
GEFA-C6 158.2  12.5 
58.0 11.4 
52.6  3.3 
27.2  6.8 
9.7  3.9 
GEFA-C8 
GEFA-C10 
GEFA-C12 
GEFA-C18 
 
In further research, MCM significantly improved the transdermal delivery flux rate 
of hydrophilic drug (progesterone) and hydrophobic drug (adenoine) though porcine 
ear skin (Hosmer et al., 2009). 
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1.3.4 Antimicrobial properties of MCM 
Medium chain fatty acids and their corresponding MCM present a broad spectrum of 
antibacterial properties in numerous studies. Early research found that glycerol 
monolaurate prohibited the group A, B, F, and G streptococci with 10 to 20 g/mL 
concentrations (Schlievert et al., 1992). Glycerol monolaurate has also demonstrated 
antimicrobial activity against Staphylococcus aureus and Streptococcus pyogenes 
(Schlievert and Peterson, 2012). Furthermore, this study also demonstrated that 
glycerol monolaurate has the ability to inhibit Haemophilus influenza and 
Staohylococcus aureus in biofilm cultures, suggesting that glycerol monolaurate has 
the potential as a broad spectrum topical microbial agent. Monocaprin (10:0) has 
displayed rapid antimicrobial activity against Chlamydia trachomatis (Bergsson et 
al., 1998) and Candida albicans (Bergsson et al., 2001). Furthermore, monocaprin 
has been shown to reduce biofilm biomass on mucosal surface and medical 
equipment and devices (Thorgeirsdottir et al., 2006a). 
Generally, MCM possess more potent antimicrobial activity than the corresponding 
fatty acid towards various Gram-positive species. Additionally, other antimicrobial 
compounds have displayed synergy with MCM. Glycerol monolaurate and lauric 
acid have displayed synergistic antibacterial/anti-biofilm activity when combined 
with the aminoglycoside antibiotics, gentamicin and streptomycin (Hess et al., 2014). 
1.4 ME formulations as topical drug delivery vehicles 
1.4.1 Formation and structure of MEs 
MEs are defined as a single, optically isotropic structured solution of surfactant, oil 
and water is called a microemulsion (Danielsson and Lindman, 1981). MEs can be 
formed with a wide range of oil-surfactant-water compositions and can be either 
water-in-oil (W/O) or oil-in-water (O/W) with a characteristic droplet size of 150 nm 
or less (Kreilgaard, 2002). As it is difficult to predict ME formation based on the 
complex physical-chemical interactions between components, pseudo-ternary phase 
diagrams are commonly used to determine the specified oil-surfactant-water 
concentration ranges required for the formation of MEs (Chen et al., 2004, Saint 
Ruth et al., 1995, Aboofazeli and Lawrence, 1993, Kale and Allen, 1989, Rushforth 
et al., 1986). 
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A variety of structures and phases can be formed with an oil, surfactant and water 
mixture. Visual inspection can easily recognise many of these structures and phases 
from their physical appearance. Emulsions are non-transparent and the water and oil 
phases will eventually separate; lamellar structures and cubic phases have increased 
viscosity; crystalline phases can be discerned by polarised microscopy. (Kreilgaard, 
2002) The interface in the MEs is continuously and spontaneously fluctuating. MEs 
are dynamic systems and are significantly affected by the composed components. 
Both the physio-chemical properties of the components and the ratio between the 
components can affect the structure of ME systems (Lam and Schechter, 1987). 
Monophasic ME are of consideration as potential drug delivery vehicle in this study 
since they are stable, can be easily prepared and have a high capacity for a wide 
range drug solubilisation, including lipophilic and hydrophilic compounds in the one 
formulation (Lawrence and Rees, 2000). Depending on the properties of the 
components, the structure of a ME, can range from being spherical droplets to coarse 
agglomerates (Santos et al., 2008). 
1.4.2 ME formulation for topical drug delivery 
MEs can satisfy all requirements for liquid drug delivery vehicles including 
thermodynamic stability (long shelf-life), easy production (zero interfacial tension 
and almost spontaneous formation), low viscosity with Newtonian behavior, and 
high solubilization capacity. MEs were chosen as ideal liquid vehicles for drug 
delivery since the small droplets have better ability to adhere to membranes and to 
transport bioactive molecules in a more controlled fashion. (Shakeel et al., 2008) 
MEs can be administered into the body orally, topically on the skin, or nasally, as an 
aerosol for direct entry into the lung (Kogan, 2006). 
MEs have been studied in the last decades since their great potential in many 
applications. Significant efforts have obtained due to MEs’ complicated phase 
behavior and fascinating microstructures in ME forming systems (Hellweg, 2002, 
Langevin, 1992, Schulman et al., 1959, Strey, 1994, Strey, 1996). In spite of these 
benefits, only few drug formulations are commercially available in the market. The 
dog shampoo “Allermyl®” produced by Virbac® in USA is a ME based application 
for dogs and cats. It is designed to clean and release the irritation condition in pets’ 
skin (Virbac, 2011). Another ME based formulation “Solvium” containing Ibuprofen 
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were commercially used to topical treatment, which was produced by Chefaro 
(Akzo)  (Verma and Hassan, 2013). However, the function of human skin provides a 
primary barrier to transdermal delivery (Kreilgaard, 2002). 
1.5 The aim of this study 
MCM (C6-12) are known transdermal penetration enhancers that have been used for 
the transdermal delivery of a range of compounds (Lopes et al., 2005, Lopes et al., 
2009, Hosmer et al., 2009, Lopes et al., 2007). Furthermore, MCM display broad 
spectrum antimicrobial activity against a variety of human pathogens (Isaacs et al., 
1995, Thorgeirsdottir et al., 2006b, Bunkova et al., 2011, Hyldgaard et al., 2012).  
This combination of activities displayed by MCM may be useful in the development 
of novel antimicrobial formulations for topical use. MEs are stable mixtures of oils, 
surfactants and water and are ideal for the development of topical formulations 
containing MCM and water-soluble drug compounds. Therefore, the broad aim of 
this project was to investigate the use of MCM as a transdermal permeation enhancer 
for water soluble compounds in ME formulations. The specific aims were:  
1. To identify suitable surfactant/co-surfactant combinations that enable stable 
incorporation of MCM into ME formulations. 
2. To examine the effect of surfactant/co-surfactant combinations on the 
transdermal permeation enhancing properties of MCM. 
3. To develop and assess a topical ME formulation for the transdermal delivery 
of the topical antibiotic, gentamicin. 
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2 METHODS AND MATERIALS 
2.1 Materials 
2.1.1 Chemicals 
Span 80-LQ-(SG) and Crodamol GTCC-LG-(SG) were supplied as a gift by 
CRODA, Singapore Pty Ltd. Tween 80-LQ-(SG) and BRIJ-O10-SS-(R13) were 
purchased from CRODA Australia. Tween 20, Tween 40 and Tween 60 were 
purchased from Sigma-Aldrich (USA). Kolliphor EL was a gift from BASF 
Australia. Gentamicin sulfate salt and 1, 2 - Decanediol (C8) were from SIGMA – 
ALDRICH. Capmul MCM (C8) (EP) and Captex 300 EP/NF were supplied as a gift 
from ABITEC Corporation. Gentamicin [3H(G)] sulfate was purchased from 
American Radiolabeled Chemicals, Inc. Fluorescein sodium salt was purchased from 
Fluka Analytical Sigma. Monocaprylin (C8) was obtained from NU-CHEK Prep 
(USA). Hydrogen peroxide (30%) and ethanol 100% undenatured (Ethyl Alcohol 
100%) were supplied by Liem Supply and Chem-Supply. Solvable and Ultima Gold 
were purchased from PerkinElmer (USA). All other solvents and reagents were 
commercial products of analytical grade and were used without further purification. 
Milli-Q water (MilliPore, VIC) was used throughout. 
2.1.2 Equipment 
The Franz diffusion cells (9mm diameter, 5mL volume) and 6 place stirrers were 
manufactured by PermeaGear (USA) and the circulating water bath was 
manufactured by HAAKE (USA). Handheld LCR Meter U1733C was manufactured 
by Agilent (Australia). POLARstar Omega plate reader and Liquid Scintillation 
Analyzer were ordered from BMG LABTECH (Australia) and PerkinElmer (USA), 
respectively. 
2.1.3 Animals 
Mice: C57BL/6J mice aged 8-12 weeks. C57BL-6J mice were sourced from 
Australian BioResources, Moss Vale. 
2.2 Construction of Pseudo-Ternary Phase Diagram 
Pseudo-ternary phase diagrams were prepared according to the procedure described 
by (Li et al., 2005). Mixtures of oil and surfactant were prepared in 5 mL flat bottom 
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tube in the following ratios: 1: 9, 2: 8, 3: 7, 4: 6, 5: 5, 6: 4, 7: 3, 8: 2 and 9: 1. After 
equilibration for 10 min at room temperature, aliquots of the oil/surfactant mixtures 
were mixed with varying amounts of Milli-Q water (10% to 90% w/w). After 
shaking for 5 min, the solutions were allowed to equilibrate overnight. The solutions 
were characterised by visual observation and classified as either: (1) MEs which 
appeared as clear or translucent, single phase solutions or (2) unstable emulsions 
which appeared as cloudy solutions that phased-separated overtime or after 
centrifugation at 14000 x g for 5 min. 
A Microsoft Excel spreadsheet named “Tri-plot v1.4.2” was used to prepare the 
triangular phase diagrams for particle shape and tri-variate date. Adobe Photoshop 
CS6 was used to describe variable phases and specific ME samples. The monophasic 
region (AT) was the percentage of ME area in the total phase diagram area. In this 
article, the pixel amounts of ME area and total phase diagram area were counted by 
Adobe Photoshop CS6, which can be used to calculate the AT. 
2.3 Measuring transdermal permeation rate through hairless mice skin 
2.3.1 Collection of skin tissue from mice 
For transdermal permeation experiments conducted in vitro, murine skin tissue was 
collected from animals made available through a tissue sharing arrangement with 
different researchers at the University of Wollongong with approval from the 
University’s Animal Ethics Committee (AE14/23).  Mice that had been sacrificed via 
CO2 exposure (within 30 min prior), had their backs shaved using electric hair 
clippers. The shaved skin area was then surgically excised, removed of all 
subcutaneous fat and tissue before being laid flat in a labelled snap lock bag and 
stored at -20 °C. 
2.3.2 Mounting full thickness mice skin to Franz diffusion cells 
The skin tissue was defrosted at 4 °C for 20 minutes, then allowed to heat to room 
temperature for 10 minutes. The skin was cut into small sections that completely 
covered the reception chamber (approximately 1.5 cm2). The skin was placed onto 
the receptor chamber (epidermal side was up). The donor chamber was then placed 
on top of the skin and clamped in position (Fig 2.1). The reception chamber was 
filled with 5 mL of degassed phosphate buffered saline (PBS) pH 7.4 ensuring no air 
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bubbles were trapped under the skin. A stirrer bar was added to receptor chamber and 
the assembled diffusion cell was placed into the 6-place magnetic stirrer.  The Franz 
cells were connected to a recirculating water bath to maintain the temperature at 35 
°C. 
2.3.3 Assessing the integrity of full thickness hairless mice skin 
The integrity of mouse skin was assessed by measuring the electrical resistance 
across the skin when mounted in the Franz cell. 400 μl PBS was added in the donor 
chamber and allowed to be equilibrated for 5 minutes. Resistance was measured 
using a handheld LCR meter (Agilent U1733C) fitted with platinum wire electrodes, 
set at 100 Hz in parallel (PAR) mode. The electrodes were inserted into Franz cell as 
shown in Fig 2.1 taking care not to touch the skin. For intact skin, resistance was in 
the range of 6 to 15 kΩ/cm2 (Novotny et al., 2009). Skin sections with resistance 
below this range were discarded. 
 
Fig 2.1 Location of the electrodes when measuring the resistance across skin 
mounted in Franz diffusion cells. 
2.3.4 Measuring the transdermal permeation of sodium fluorescein 
For formulations containing sodium fluorescein (NaFlu), a 200 µL aliquot was 
applied to the donor chamber at NaFlu concentration of 1.2 mg/mL. Aluminium foil 
was used to loosely cover the top of the receptor chamber and donor chamber to 
prevent excessive evaporation. A 100 μL or 200 μL aliquot of receptor fluid was 
collected at specified time points during the course of the experiment (24 h) and was 
immediately mixed with an equal volume of 10 mM NaOH. To maintain constant 
sink conditions, the receptor chamber fluid was maintained at 5 mL by adding an 
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equal volume of degassed PBS to replace the aliquot that was withdrawn. For the 
duration of the experiment, the Franz cell apparatus and collected samples were 
protected from light. The fluorescence intensity of each sample was measured using 
a POLARstar Omega plate reader (BMG LABTECH). Plate reader setting are given 
below. The optimal gain setting was set automatically on samples from the last time 
point. The amount of NaFlu present in each sample was determined from a standard 
curve of NaFlu (0 μg/ml to 20 μg/mL) which was included on each plate. The 
standard curve was linear in the range of 0 to 1.3 μg/mL. 100 μl samples were added 
in the same plate.  
The transdermal flux rate (Js) was the ratio of the change in cumulative drug amount 
per mouse skin area against the different of collect time point (ng/cm2/h): 
Flux rate =  
𝛥𝑚
𝑆 ∙ 𝛥𝑡
 
𝛥𝑚 = The different of cumulative drug amount (ng) 
𝛥𝑡 = The change in diffusion time (h) 
𝑆 = The area of mouse skin (0.64 cm2) 
The cumulative amount permeated (Q24h) through full thickness mouse skin was the 
total amount of drug accumulated in the reception chamber after 24 hours divided by 
the mouse skin area (ng/cm2). 
𝑇ℎ𝑒 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑒𝑟𝑚𝑒𝑎𝑡𝑒𝑑 =
𝑚
𝑆
 
m = The drug amount collected after 24 hours (ng) 
S = The area of mouse skin (0.64 cm2) 
Details of the protocol: 
Emission: 520     Excitation: 485-12 
Orbital Averaging: ON   Diameter: 4 mm 
Top optic     Position delay: 0.1 
Measurement start time: 0.0   Number of flashes per well: 10 
Replicates Number: 2    Unit: nmL 
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Start concentration: 2,000,000  Factor: 0.5 
Start Volume: 200    Factor: 1 
Shaking Model: Orbital   Shaking Frequency: 500 rpm 
2.3.5 Measuring the transdermal permeation of gentamicin 
For formulations containing tritium labelled gentamicin, 20 µl aliquot was applied to 
the donor chamber at gentamicin concentration. Each contains 10 mg/mL gentamicin 
that was spiked with 0.5 µCi of tritium labelled gentamicin. Aluminium foil was 
used to loosely cover the top of the receptor chamber and donor chamber to prevent 
excessive evaporation. A 200 μl aliquot of receptor fluid was collected at specified 
time points during the course of the experiment (24 h). To maintain constant sink 
conditions, the receptor chamber fluid was maintained at 5 mL by adding an equal 
volume of degassed PBS to replace the aliquot that was withdrawn.  
After all samples in the receptor chamber were collected, 400 µl PBS was used to 
wash the skin while in the donate chamber of Franz cell, repeat this and store the 
wash in tubes. Donor chambers and clamps were taken off after the wash. Skin tissue 
was removed and placed in glass scintillation vials containing 3mL Solvable. The 
vials were incubated in the incubator at 50 °C for 4 hours or more, until the tissue is 
completely dissolved. Remain buffer from receptor chamber was removed into a 
radioactivity waste bottle. 10 μl original radiolabelled formulation was diluted with 
90 μl PBS and filled in glass scintillation vials. 100 μl of sample from the wash 
buffer, the skin solution and the receptor chamber were mixed with 5 mL Ultima 
Gold scintillation cocktail (PerkinElmer), respectively, adding in each scintillation 
vial. All vials were numbered on lids and mixed thoroughly by inversion. Remain 
buffer from receptor chamber was removed into a radioactivity waste bottle. 
All the bottles were placed in the Liquid Scintillation Analyzer (PerkinElmer Tri-Cab 
2810TR) and run protocol (Flag 2: JMC dpm) to measure the level of radioactivity. 
The protocol (Flag 2: JMC dpm) has the following parameters:  
Assay Type: Direct DPM  Radionuclide Name: Direct DPM 3H-UG 
Normalization Std DPM: 259700 Quench Set: 3H-UG Quench 
Indicator: tSIE/AEC   External Std Terminator: 0.5 2s% 
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Static Controller was selected. 
After measurement finish, the value of raw DPM was obtained (recorded in the 
DPM1 row). The value of raw DPM times the dilution factor to get the corrected 
DPM. The absolute amounts of accumulated gentamicin through the skin area 
present in the samples (ng/cm2) was able to be calculated by the following equation: 
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑟𝑢𝑔 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑠𝑘𝑖𝑛 =
𝑚(𝑠𝑡)
𝑆
∙
𝐷𝑃𝑀(𝑠)
𝐷𝑃𝑀(𝑠𝑡)
  
𝐷𝑃𝑀(𝑠) =  The raw DPM of sample times dilution factor (50)   
𝐷𝑃𝑀(𝑠𝑡) = The raw DPM of 100% dose sample times dilution factor (4)  
𝑚(𝑠𝑡) = The amount of drug applied in the 100% dose sample (200 µg) 
𝑆 = The area of mouse skin (0.64 cm2)  
2.4 Bio-distribution studies in mice 
To permit the topical application of formulations directly to skin, the rear flank 
region of mice was shaved using electric animal clippers.  This was performed two 
days prior to the commencement of the experiment. 
Mice were divided into 3 treatment groups of 20 individuals as shown in table 2.1. 
Mice were topically treated with either PBS containing 10 mg/mL gentamicin, one 
dose of the ME containing 10 mg/mL or 2 identical doses of the ME containing 10 
mg/mL (See Table 2.2). All formulations were spiked with 1 µCi of tritium labelled 
gentamicin (American Radiochemicals, St. Louis USA). To topically apply the 
radiolabeled formulations, each mouse was anaesthetised using isoflurane and 20 µl 
of the specified formulation was pipetted onto the shaved area skin.  To avoid mice 
ingesting the formulation applied to their flanks, animals were fitted with an 
Elizabethan collar (Kent Scientific, Torrington, USA) while anaesthetised.  After 
treatment, mice were caged individually for the duration of the experiment 
(maximum 48 hours) to prevent inter-animal grooming. These cages were also free 
of nesting material and PVC enrichment tubes for this period. 
At specified time points post treatment (Table 2.1), 4 mice from each group were 
sacrificed using CO2, dissected and blood/tissues collected for analysis. Blood/tissues 
were stored frozen at -20°C until processed. Tissues collected post mortem included 
skin (site of application and a distant site) and muscle (underneath the site of skin 
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collected), blood and major clearance organs such as spleen, liver, lungs, kidney. To 
determine if lymphatic circulation is influencing bio-distribution post topical  drug 
delivery (King et al., 2003), the major lymph nodes (lumbar, axillary and brachial) 
were also collected. To demonstrate mice weren’t ingesting the topically applied 
formulations, small intestine tissue was also collected and assessed.  
Table 2.1 Mice grouping use for bio-distribution studies. 
Time Points (h) 
Group 
3 6 12 24 48 Total 
PBS Group n=4 n=4 n=4 n=4 n=4 20 
ME Group n=4 n=4 n=4 n=4 n=4 20 
MEx2 Group n=4 n=4 n=4 n=4 n=4 20 
Overall Total 60 
Table 2.2 Topical formulations used for bio-distribution studies. 
Formulation Ingredients Concentration Dose Applied 
PBS Group Phosphate buffered saline 
Gentamicin  
100% 
10 mg/mL 
6.67 mg/kg 
ME Group Capmul MCM C8 
Ethanol 
Tween 80 
Water 
Gentamicin 
10% w/w 
10% w/w 
20% w/w 
60% w/w 
10 mg/mL 
6.67 mg/kg 
MEx2 Group Capmul MCM C8 
Ethanol 
Tween 80 
Water 
Gentamicin 
10% w/w 
10% w/w 
20% w/w 
60% w/w 
10 mg/mL 
13.34 mg/kg 
For each organ and blood collected from the mice, 1 mL Solvable (Pekin Elmer) was 
added. The mixture was incubated at 50°C overnight. After which taking 100 µl from 
the mixture and add 5 mL Ultima Gold scintillation cocktail (PerkinElmer) in the 
scintillation vial, 0.2 mL of 30% H2O2 was added. All vials were measured by Liquid 
Scintillation Analyzer (PerkinElmer Tri-Cab 2810TR) and run protocol (Flag 2: JMC 
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dpm) to measure the level of radioactivity. The tissue uptakes were calculated as the 
percentage of the accumulated gentamicin per gram of tissue (mg/g or mg/mL). 
2.5 Statistical analysis and software 
Original data was initially recorded and calculated in Microsoft Excel. Statistical 
analyses and comparison figures were generated by Prism 6. One-way ANOVA (and 
nonparametric) was used to analyze in vitro permeation test. Two-way ANOVA was 
used to analyze in vivo bio-distribution test. 
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3 DEVELOPING ME FORMULATIONS CONTAINING MEDIUM CHAIN 
GLYCERIDES FOR TRANSDERMAL DELIVERY 
3.1 Introduction 
Medium chain (C6~C12) chain fatty acids, mono-, di-, and tri-glycerides have been 
used in emulsion formulations as absorption enhancers for a variety of drug 
compounds (Constantinides et al., 1994). Furthermore, MCM have also been shown 
to act as transdermal permeation enhancers (Cornwell et al., 1998, Furuishi et al., 
2007). Previous research using the biocompatible components; medium chain 
triglycerides (Crodamol GTCC), medium chain monoglycerides (Capmul MCM C8), 
surfactants polysorbate 80 (Tween 80) and sorbitan mono-oleate (Span 80) and water 
indicated that ME can be formed with specific ratios of these substances 
(Watnasirichaikul et al., 2000). Recently, a ME formulation from this system was 
used to facilitate the transdermal delivery of proteins (Russell-Jones and Himes, 
2011, Himes et al., 2011). 
3.1.1 Characterization of a biocompatible ME system containing medium 
chain glycerides 
To investigate the transdermal permeation enhancing properties of these ME 
formulations, a representative pseudo-ternary phase diagram of the same system 
containing Capmul MCM C8: Crodamol GTCC (1:3, w/w), as the oil phase, 
Tween80: Span80) (3:2, w/w, as the surfactant phase and water was constructed and 
is shown in Fig 3.1. The ME formulation identified in a previous study 
(Watnasirichaikul et al., 2000) and used in the following experiments (76% MCM: 
GTCC (1:3) and 14% Tween80: Span80 (3:2), 10% water) is indicated at position A 
(Fig 3.1). 
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Fig. 3.1 Pseudo-ternary phase diagram for a mixture of medium chain glycerides 
(Capmul MCM C8: Crodamol GTCC, 1:3), a mixture of surfactants (Tween 80: Span 
80, 3:2) and water. ME formulations were defined as being a single phase that was 
visually transparent, stable upon ON incubation at room temperature after vigorous 
vortexing (Garti et al., 2000). The ME phase boundary is indicated with grey shading. 
Specific formulations assessed for transdermal permeation are indicated with A, 
marked by the red point. The monophasic ME region is indicated with AT = 8.8%. 
3.1.2 In vitro transdermal delivery skin permeation assay 
In a previous study, the formulation ME_A (Fig 3.1 and Table 3.1) effectively 
delivered peptides and proteins through the stratum corneum into living epidermal 
tissue (Himes et al., 2011). To characterize the potential of this formulation for the 
transdermal delivery of small molecules, sodium fluorescein (NaFlu) was used as a 
model small compound. Additionally, the influence of individual formulation 
components on transdermal flux was also assessed (Table 3.1). All formulations 
contained 1.2 mg/mL of NaFlu and transdermal permeation of this compound 
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through full thickness mouse skin from the various formulations was determined 
using Franz diffusion cells. 
Table 3.1 Formulation composition and corresponding transdermal permeation 
parameters of NaFlu (transdermal flux rate (Js) and cumulative amount permeated 
(Q24h)) through full thickness mouse skin. All formulations contained 1.2 mg/mL 
NaFlu. 
Formulation MCM 
(% w/w) 
GTCC 
(% w/w) 
Surfactant 
(% w/w) 
Water 
(% w/w) 
Js 
(ng/cm2/h) 
Q24h 
(ng/cm2) 
ME_A 
MCM* 
Tw/Sp* 
MCM_TS 
GTCC_TS 
PBS 
19 
19 
- 
19 
- 
- 
57 
- 
- 
- 
57 
- 
14 
- 
14 
14 
14 
- 
10 
81 
86 
67 
29 
- 
270±47 
754±185 
11±2 
599±126 
15±11 
25±10 
3,990±255 
12,368±1,852 
166±27 
10,274±2,130 
148±46 
475±172 
* indicates the formulation was a visible emulsion; Abbreviations: Tw/Sp – a 
mixture of surfactants (Tween 80: Span 80, 3:2) 
The transdermal permeation profile of NaFlu from each of the formulations applied 
to full thickness mouse skin is shown in Fig 3.2. From these graphs, the maximum Js 
of NaFlu produced by each formulation and the total amount of NaFlu accumulated 
in the receptor chamber (Q24h) was determined and is presented in Table 3.1. 
Application of NaFlu dissolved in PBS produced a Js of 25 ng/cm2/h indicating that 
NaFlu does not readily pass through mouse skin. The Js produced by formulation 
ME_A (270 ng/cm2/h) was significantly higher (over 10-fold) when compared to the 
Js produced by PBS (p < 0.05). This indicates ME_A can act as a transdermal 
permeation enhancer for small compounds.  
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Fig 3.2 Cumulative transdermal permeation of NaFlu through mouse skin in vitro 
over 24 h. All formulations contained 1.2 mg/mL NaFlu and are described in Table 
3.1 except for the control formulation (PBS) which consisted of NaFlu dissolved in 
PBS solution. Each point represents the mean ± standard deviation of 3 to 4 
biological replicates. (Appendix 7.3, 7.4, 7.5, 7.6, 7.7 and 7.10) 
To determine how the individual components in formulation ME_A influenced the 
transdermal permeation of NaFlu, formulations containing these individual 
components were also examined. The application of NaFlu dissolved in either diluted 
surfactant (Tween 80: Span 80 (3:2, w/w)) or GTCC and surfactant mixture 
(GTCC_TS) to mouse skin resulted in low Js of 11 ng/cm2/h and 15 ng/cm2/h, 
respectively. Taken together, this indicates these components do not affect the 
transdermal permeation of NaFlu through mouse skin. By contrast, the Js produced 
by formulation MCM_TS (599 ng/cm2/h) and MCM alone (754 ng/cm2/h) was 
significantly higher (over 25 and 30-fold, respectively) when compare to the Js 
produced by PBS (p<0.05). This indicates MCM can act as transdermal permeation 
enhancer for small compounds. Furthermore, as there was no significant difference 
between flux rates for MCM_TS and MCM alone (p>0.05), this indicates the 
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surfactant blend (Tween 80: Span 80 (3:2, w/w)) does not influence the transdermal 
permeation enhancing properties of MCM. 
3.2 Influence of surfactant type on the transdermal permeation enhancing 
properties of MCM 
Surfactants are required to form stable ME formulations that are suitable for topical 
applications. Therefore, to determine how different surfactants influence the 
transdermal permeation enhancing properties of MCM, several surfactants were 
mixed with/without MCM (Table 3.3) and these formulations were assessed for 
transdermal permeation using NaFlu (Fig 3.3). 
Table 3.2 Formulation composition and corresponding transdermal permeation 
parameters of NaFlu (Js and Q24h) through full thickness mouse skin. All 
formulations contained 1.2 mg/mL NaFlu. 
Formulation MCM 
(% w/w) 
GTCC 
(% w/w) 
Surfactant 
(% w/w) 
Water 
(% w/w) 
Js 
(ng/cm2/h) 
Q24h 
(ng/cm2) 
MCM_CO 
MCM_BJ 
CO 
BJ 
PBS 
19 
19 
0 
0 
0 
0 
0 
0 
14 
14 
14 
14 
67 
67 
86 
86 
180±122 
991±52 
94±46 
140±90 
25±10 
1,427±523 
17,850±1336 
1,507±879 
1,162±875 
475±172 
Abbreviations: CO - Kolliphor EL, BJ - BRIJ O10  
The transdermal permeation profile of NaFlu from each of the formulations applied 
to full thickness mouse skin is shown in Fig 3.3. From these graphs, the Js produced 
and Q24h were determined and are shown in Table 3.3. The Js produced by 
application of CO (94 ng/cm2/h) and BJ (140 ng/cm2/h) were higher than the Js 
produced by PBS (25 ng/cm2/h) (p<0.05). However, these surfactants had contrasting 
effects on the transdermal permeation enhancing properties of MCM. The Js 
produced by formulation MCM_BJ (991 ng/cm2/h) was significantly higher when 
compared to the Js produced by formulation MCM alone (754 ng/cm2/h), suggesting 
a possible synergistic interaction between these compounds. In contrast, the Js 
produced by MCM_CO (180 ng/cm2/h) was significantly lower (p<0.05) when 
compared to the Js produced by MCM alone, indicating a possible antagonistic 
interaction between the MCM and Kolliphor EL. As the Js produced by MCM_BJ 
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was significantly (p<0.05) higher than the Js produced by MCM_TS and the Js of 
MCM_TS was significantly (p<0.05) higher than the Js produced by MCM_CO, this 
suggests the enhancing effect of the different surfactants on the rate of NaFlu 
transdermal permeation mediated by MCM was found to be: BRIJ O10 > 
Tween80/Span80 (1:3, w/w) > Kolliphor EL. 
 
Fig 3.3 Cumulative transdermal permeation of NaFlu through mouse skin in vitro 
over 24 hours. All formulations contained 1.2 mg/mL NaFlu and are described in 
Table 1.3. Each point represents a mean ± standard deviation of 3 to 4 biological 
replicates. (Appendix 7.3, 7.6, 7.8, 7.9, 7.10, 7.11 and 7.12) 
The Js chosen from the application of MCM was between time point 9 h and 22 h and 
from the application of MCM_BJ was between time point 12 h to 22h, which are 
both long time gap. This is because during the in vitro experiments of NaFlu, the 
sample collection time points were not unified, therefore Js may different with the 
actual flux rate and need to be tested in a smaller time interval in the future 
experiment. In the next set of experiments of gentamicin, those collection time points 
were consistently chosen. 
3.3 The effect of MCM concentration on transdermal permeation 
Based on the data presented in Table 3.2, it is evident that the combination of MCM 
and the BRIJ O10 surfactant produced the highest transdermal permeation activity. 
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To determine how BRIJ O10 can be incorporated into the ME system containing the 
MCM: GTCC oil phase, pseudo-ternary phase diagrams were constructed using the 
water titration method at ambient temperature (25 °C) and are shown in Fig 3.4. 
 
Fig 3.4 Pseudo-ternary phase diagram for a mixture of (a) medium chain glycerides 
(Capmul MCM/Crodamol GTCC, 1: 3, w/w), (b) medium chain glycerides Capmul 
MCM/Crodamol GTCC (1: 1) in combination with surfactant (BRIJ O10) and water. 
The monophasic ME region is indicated with grey shading with A T(a) = 15.4%; AT(b) 
= 33.2%. Specific formulations assessed for transdermal permeation ability are 
marked by red points and labelled with B, C, D, E and F. A dilution line (indicated 
by dotted line) was used to demonstrate the maximum water ratio when mixed with 
certain ratio oil mixture and surfactant mixture. 
It is evident that the AT in Fig. 3.4(a) is less than that in Fig. 3.4(b). This suggests 
that increasing the ratio of MCM in oil phase from 25% to 50% in the 
MCM/GTCC/BRIJ system produces a larger AT. 
From the pseudo-ternary phase diagram in Figure 3.4 (b), a dilution line within the 
single-phase region at the lowest possible concentration of surfactant was identified. 
A selection of formulations from along this dilution line (labelled ME_C, ME_, 
MG_D, MG_E and MG_F; see Fig 3.4 and Table 3.3) were used to investigate how 
MCM concentration influences the transdermal permeation properties of 
MCM/GTCC based formulations. 
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Table 3.3 Formulation composition and corresponding transdermal permeation 
parameters of NaFlu (Js and Q24h) through full thickness mouse skin. All 
formulations contained 1.2 mg/mL NaFlu. 
Formulation 
 
MCM 
(% w/w) 
GTCC 
(% w/w) 
Surfactanta 
(% w/w) 
Water 
(% w/w) 
Js 
(ng/cm2/h) 
Q24h 
(ng/cm2) 
ME_B 
ME_C 
ME_D 
ME_E 
ME_F 
PBS 
24.5 
17.5 
14 
10.5 
7 
- 
24.5 
17.5 
14 
10.5 
7 
- 
21 
15 
12 
9 
6 
- 
30 
50 
60 
70 
80 
- 
570±284 
716±179 
324±217 
254±225 
1,021±396 
25±10 
8,489±1029 
7,369±1436 
5,300±3161 
3,119±2289 
 10,583±4324 
475±172 
a The surfactant used in all formulations was BRIJ O10. 
 
Fig 3.5 Time course of the in vitro transdermal permeation of NaFlu from 
MCM/GTCC/BRIJ based formulations over 24 hours. Each point represents a mean 
± standard deviation of 3 to 4 replicates. ME formulations ME_B, ME_C, ME_D, 
ME_E and ME_F contained 24.5%, 17.5%, 14%, 10.5% and 7% (w/w) MCM_C8 
respectively (Table 3.3). NaFlu was used as model drug with 1.2 mg/mL 
concentration applied to full thickness mouse skin. (Appendix 7.3, 7.13, 7.14, 7.15, 
7.16 and 7.17) 
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The transdermal permeation profile of NaFlu from each of the formulations applied 
to full thickness mouse skin is shown in Fig 3.5. From these graphs, the maximum Js 
of NaFlu produced by each formulation and the accumulated amount of NaFlu in the 
receptor chamber (Q24h) was determined (Table 3.3). Application of NaFlu dissolved 
in PBS was used as a negative control group. 
All formulations were able to significantly enhance the transdermal permeation of 
NaFlu through mouse skin (p<0.05) although the flux rates produced by the different 
formulations were variable. Formulation ME_F (7% w/w MCM) produced the 
highest Js (1,021 ng/cm2/h) which was over 40-fold greater than the Js produced by 
NaFlu in PBS. Formulation ME_E produced the lowest Js (254 ng/cm2/h). The Js 
produced by ME_E was the lowest and was significantly lower comparing to the J s 
produced by ME_F (p<0.05). While these data demonstrate the ability of all 
formulations to enhance the transdermal permeation of NaFlu, there was no 
correlation between the MCM concentration and the transdermal flux produced by 
the formulation (Fig 3.6). 
 
Fig. 3.6 The relationship between the concentration of MCM in the ME formulation 
and the corresponding Js of NaFlu (ng/cm2/h) through full thickness mouse skin. 
Each point represents an individual sample replicate. All formulations contained 
NaFlu at 1.2 mg/mL. 
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Linear regression analysis was processed in Prism 6. The correlation trend is 
indicated by the blue line and the correlation coefficient is 0.137.  (R2 = 0.019, P-
value = 0.555)  
3.4 Characterizing the influence of ethanol as a co-surfactant on the ME 
systems containing MCM 
In previous studies, the co-surfactants such as a short- or medium-chain alcohols are 
used to reduce the interfacial tension of ME formulations. While alcohols may 
potentially cause skin irritation and dehydration, ethanol is considered safe for 
topical formulations where the contact time on skin is short (Morgan et al., 1998). 
Therefore, to characterize the influence of ethanol on MEs systems containing MCM, 
pseudo-ternary phase diagrams were constructed using different amounts of Capmul 
MCM C8: ethanol (1:1, w/w) as the oil phase, surfactants (either BRIJ O10, 
Kolliphor EL, Tween 20 and Tween 80) and water (Fig 3.8). Comparing the AT value 
of single phase areas between these systems that utilised different surfactants 
indicated there were only slight differences with Kolliphor EL (52.7%) > BRIJ O10 
(52.3%) > Tween 80 (50.9%) > Tween 20 (41.2%). 
Comparing the AT values of Fig 3.7 (a) to Fig 3.4 (b), it is evident that the 
monophasic areas in MCM/EtOH based phase diagrams are larger than that of 
MCM/GTCC based phase diagram, indicating the ethanol increased the AT when 
incorporated with Capmul MCM and BRIJ O10. 
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Fig 3.7 Pseudo-ternary phase diagrams for a mixture of MCM and EtOH (Capmul 
MCM: EtOH, 1:1, w/w) and surfactants BRIJ O10 (a), Kolliphor EL (b), Tween 20 
(c), Tween 80 (d) in combination with water. The AT is indicated with grey shading 
with AT(a) = 52.3%; AT(b) = 52.7%; AT(c) = 41.2%; AT(d) = 50.9%. Specific 
formulations ME_BJ, ME_CO, ME_T2 and ME_T8 assessed for transdermal 
permeation rate are indicated with G, H, I and J on phase diagrams, marked by red 
points. 
Formulation ME_BJ (G), ME_CO (H), ME_T2 (I) and ME_T8 (J) (Table 3.4) were 
selected by identifying the lowest surfactant concentration present in the ME region 
that was common to all four surfactant systems examined. The transdermal 
permeation profile of NaFlu from each of the formulations applied to full thickness 
mouse skin is shown in Fig 3.8. The maximum Js of NaFlu produced by each 
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formulation and the total amount of NaFlu accumulated in the receptor chamber was 
determined and is presented in Table 3.4. The Js produced by formulation ME_BJ 
was significantly higher (over 33-fold) when compared to the Js produced by PBS 
(p<0.05). The Js produced by formulation ME_T8 was significantly higher (over 29-
fold) when compared to the Js produced by PBS (p<0.05). The Js produced by 
formulation ME_CO was significantly higher (over 10-fold) when compared to the Js 
produced by PBS (p<0.05). The Js produced by formulation ME_T2 was 
significantly higher (over 4-fold) when compared to the Js produced by PBS 
(p<0.05). All above indicate that ME_BJ ME_T8, ME_CO and ME_T2 can act as a 
transdermal permeation enhancer for small compounds. 
Table 3.4 Formulation composition and corresponding transdermal permeation 
parameters of NaFlu (Js and Q24h) through full thickness mouse skin. All 
formulations contained 1.2 mg/mL NaFlu. 
Formulationa 
 
MCM 
(% w/w) 
EtOH 
(% w/w) 
Surfactant 
(% w/w) 
Water 
(% w/w) 
Js 
(ng/cm2/h) 
Q24h 
(ng/cm2) 
ME_BJ 
ME_CO 
ME_T2 
ME_T8 
MCM/EtOH 
PBS 
10 
10 
10 
10 
10 
- 
10 
10 
10 
10 
10 
- 
20 
20 
20 
20 
0 
- 
60 
60 
60 
60 
80 
- 
846±159 
269±187 
123±28 
732±169 
2,267±926 
25±10 
13,523±2,135 
4,109±1,974 
1,817±303 
13,225±1,154 
33,111±11451 
475±172 
a Surfactants used in the following formulations: BRIJ O10 (ME_BJ); Kolliphor EL 
(ME_CO); Tween 20 (ME_T2); Tween80 (ME_T8). No surfactant was used in 
MCM/EtOH. Abbreviations used; MCM - Monoglycerides, EtOH - ethanol. 
There is no significant difference between the Js produced by ME_BJ (846 ng/cm2/h) 
and ME_T8 (732 ng/cm2/h) (p > 0.05). Meanwhile, there is no significant difference 
between the Js produced by ME_CO (269 ng/cm2/h) and ME_T2 (123 ng/cm2/h) (p > 
0.05). However, the Js produced by both application of ME_BJ and ME_T8 were 
significantly higher when compared to the Js produced by both application of 
ME_CO and ME_T2, respectively (p<0.05). The application of NaFlu dissolved in 
MCM/EtOH produced the highest Js of 2267 ng/cm2/h comparing to all other 
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formulations (P<0.05) indicating the MCM/EtOH mixture promotes the transdermal 
permeation for small compounds. 
Comparing the transdermal permeation properties of MCM/EtOH and MCM alone 
(Table 3.1), the Js produced by formulation MCM/EtOH (2267 ng/cm2/h) was 
significantly higher (3-fold) than the Js produced by MCM (754 ng/cm2/h) (p < 0.05). 
Since the concentration of MCM/EtOH (20%) is quite close to the concentration of 
MCM (19%), this suggests there may be a possible synergistic interaction between 
MCM and ethanol which increases the transdermal permeation performance of 
formulations that contain both substances. Besides, the Js produced by ME_BJ was 
the highest (846 ng/cm2/h) comparing to other MCM/EtOH based ME formulations. 
This result is quite similar to the performance of BRIJ O10 containing formulation in 
MCM/GTCC based formulations (Table 3.2). 
 
Fig 3.8 Cumulative NaFlu transdermal delivery for MCM/EtOH based formulations 
within 24 hours. BRIJ O10 (ME_BJ), Kolliphor EL (ME_CO), Tween 20 (ME_T2) 
and Tween 80 (ME_T8) were incorporated with MCM/EtOH (1:1, w/w) respectively, 
each containing NaFlu 1.2mg/mL. Each point represents means ± standard deviation 
of 3 to 4 biological replicates. (Appendix 7.3, 7.18, 7.19, 7.20, 7.21 and 7.22) 
Taken together, these data suggest that the combination of MCM/EtOH significantly 
enhanced the formulation transdermal delivery property for small compounds. 
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Moreover, surfactant BRIJ O10 and Tween80 performed better permeation enhancer 
property than other surfactants along the MCM/EtOH based systems. 
 
3.5 Discussion 
To initially characterise the ME formulation used by Himes et al. (2011) and Russell-
Jones and Himes (2011) for the transdermal delivery of protein, a pseudo-ternary 
phase diagram was constructed using the same components (i.e. a 3:1 mixture of 
medium chain triglycerides (Crodamol GTCC) and MCM (Capmul MCM C8), a 3:2 
mixture of polysorbate 80 (Tween 80) and sorbitan mono-oleate (Span80) surfactants 
and water). Comparing this phase diagram (Fig 3.1) with a similar one constructed 
previously by Watnasirichaikul et al. (2000), MEs were formed under similar 
conditions (where oil/surfactant ratio is between 10:90 and 90:10 with water ≤ 10% 
w/w). The maximum percentage of water solubilized in the system was found to be 
10% w/w, which is lower than 14% w/w in the study by Watnasirichaikul et al. 
(2000). However, if smaller increments of water were used for the titration, a more 
accurate phase diagram would be produced allowing for a better comparison between 
the two-phase diagrams. 
For transdermal permeation studies, NaFlu was used as a model, small hydrophilic 
compound as it can be readily quantified using fluorescence spectroscopy. This 
model compound is commonly used in transdermal permeation studies (Santos et al., 
2008, Valenta and Schultz, 2004). In this study, formulation ME_A (Himes et al. 
(2011) promoted the transdermal delivery of NaFlu through full thickness mouse 
skin at a flux rate of 270 ng/cm2/h, which was over 10-fold higher when compared to 
NaFlu in PBS (25 ng/cm2/h). This indicates that formulation ME_A has the potential 
to be used as a transdermal permeation enhancing formulation for small compounds. 
To further characterise this formulation, individual components of the ME_A 
formulation were examined alone or in combination to evaluate how they influenced 
the transdermal permeation flux rate of NaFlu. While GTCC and the surfactant blend 
had no effect on the transdermal permeation of NaFlu when used alone, MCM 
significantly increased (over 30-fold) the Js of NaFlu (754 ng/cm2/h) when compared 
to the Js produced by NaFlu in PBS indicating MCM acts as the permeation enhancer 
in formulation ME_A. In this study, a core role of the in vitro transdermal 
 
 
 
35 
experiment is to determine the ME formulation with relative high Js value. However, 
when GTCC and the surfactant blend were mixed with MCM in the ME_A 
formulation, the Js was significantly lower (p < 0.05) when compared to the Js 
produced by MCM alone. Taken together, these experiments indicate that presence 
of GTCC in the formulation decreased the transdermal permeation enhancing 
properties of MCM. 
It should be noted that the Js chosen from the application of MCM was between time 
point 9 h and 22 h and from the application of MCM_BJ was between time point 12 
h to 22h, which are both long time gap (Fig 3.3). This is because during the in vitro 
experiments of NaFlu, the sample collection time points were not unified, therefore Js 
may different with the actual flux rate and need to be tested in a smaller time interval 
in the future experiment. In the next set of experiments of gentamicin, those 
collection time points were consistently chosen. 
In this study, the influence of different surfactants on the transdermal permeation 
enhancing properties of MCM were investigated. The inclusion of surfactants in the 
topical formulations can enhance transdermal permeation via partially extracting 
extracellular lamellar lipids from the stratum corneum (Albanesi et al., 2005). 
Additionally, surfactants may also increase the fluidity of the intercellular lipid phase 
permitting increased diffusion of small molecules (Huzil et al., 2011). Furthermore, 
as many chemical permeation enhancers act by increasing the partition of active 
compounds in the stratum corneum, a titration of drug concentrations should be the 
subject of future studies to determine how this influences the transdermal flux rates 
for various compounds (Barry, 1983).  
The transdermal permeation profiles of surfactant test alone (Tween 80: Span 80 (3:2, 
w/w), BRIJ O10 and Kolliphor EL) were all significantly lower (p < 0.05) in 
comparison with that produced by ME_A application. In comparison with the 
transdermal permeation profile of PBS application (25 ng/cm2/h), the application of 
BJ (140 ng/cm2/h) and CO (94 ng/cm2/h) were slightly higher (p < 0.05) while the 
application of Tw/Sp (11 ng/cm2/h) was slightly lower (p < 0.05). These results show 
that either BRIJ O10, Kolliphor EL or Tw/Sp could only slightly influence the 
transdermal permeation rate when applying individually. However, when the 
surfactants were individually mixed with MCM and assessed for transdermal 
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permeation, the NaFlu Js produced by the MCM_BJ formulation (991 ng/cm2/h) was 
significantly higher (p < 0.05) when compared to that produced by MCM alone (754 
ng/cm2/h), while the Js of NaFlu produced by the MCM_CO formulation (180 
ng/cm2/h) was significantly lower (p < 0.05). The Js of NaFlu produced by MCM_TS 
(599 ng/cm2/h) similar to that produced by MCM alone. Taken together, these data 
indicate different surfactants can have varying effects on the transdermal permeation 
enhancing activity of MCM and suggest BRIJ O10 may act synergistically with 
MCM, Kolliphor EL may act antagonistically and the Tween 80: Span 80 (3:2, w/w) 
blend has no effect. The different behaviours of BRIJ O10, Tween 80: Span 80 (3:2, 
w/w) and Kolliphor EL may be the result of distinct interactions with the stratum 
corneum. Savić et al. (2009) assessed the colloidal structures and in vitro permeation 
performance of topical vehicles contain two model drugs (diclofenac sodium and 
caffeine) incorporated with three different lipophilic excipients (GTCC, decyl oleate 
and isopropyl myristate). The results suggested that the colloidal structures of topical 
delivery vehicles may affect the diffusion through the vehicles and influence their 
permeation performance. Formulations used to produce pseudo-ternary phase 
diagrams can be further characterized by measuring their electrical conductivity and 
rheological properties (Podlogar et al., 2005, Kreilgaard et al., 2000). Conductivity 
can be used to identify inversion points where the formulations transition from oil in 
water to water in oil emulsion. Furthermore, viscosity and conductivity are known to 
sharply increase when emulsion droplets cluster at the percolation threshold (i.e. in a 
bicontinuous ME) (Promod Kumar; Mittal, 1999, Gradzielski and Hoffman, 1999, 
Podlogar et al., 2004). 
To further evaluate, it is necessary to characterize those vehicles with polarization 
micrographs, conductivity measure and rheological test. Now that stable, transdermal 
permeation enhancing formulations have been identified in this study, specific 
formulations should be examined in more detail in future studies to characterize the 
physical properties (such as the size and morphology of particles) of the 
formulations. Furthermore, the solubility of various hydrophilic and hydrophobic 
compounds should be assessed and a titration of different drug concentrations in 
formulations should be assessed to determine how these properties influence 
transdermal permeation kinetics. 
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As can be seen in the pseudo-ternary phase diagram of the original 
MCM/GTCC/Tween 80: Span 80 (3:2, w/w) system used by Himes et al. (2011), the 
range of suitable component concentrations that can be utilized for the production of 
single phase, stable, biocompatible ME formulations is reflected by the AT zone (see 
Fig 3.1). Systems with greater AT zones, as determined in pseudo-ternary phase 
diagrams have a larger range of stable ME formulations that can be selected for their 
biocompatibility and drug solubilizing properties. Different surfactants and co-
surfactants can influence the interfacial forces in emulsions, a selection of 
surfactants/co-surfactants were assessed for their effect on ME formation. The non-
ionic surfactant BRIJ O10 has been used successfully in ME systems previously 
(Kogan, 2006), therefore a new pseudo-ternary phase diagram consisting of 
MCM/GTCC (1:3, w/w), BRIJ O10 and water was constructed in Fig 3.4 (a). The 
use of this surfactant produced a larger AT (26.5%) when compared to the ME_A 
which contained the Tween 80: Span 80 (3:2, w/w) surfactant blend (AT=12.5%). In 
research conducted by Prajapati et al. (2012), it was determined that ME regions can 
be expanded by increasing the concentration of MCM in the oil phase of mixture 
systems. Therefore, a mixture system of MCM: GTCC (1:1, w/w), BRIJ O10 and 
water was characterized through the construction of a new phase diagram (Fig 
3.4(b)) and compared to the MCM/GTCC (1:3, w/w), BRIJ O10 and water system 
(Fig 3.4 (a)). Increasing the concentration of MCM in these systems did produce an 
increased monophasic area. The alternative of MCM content may influence ME 
system converting gel region (bicontinuous structures) into W/O or O/W systems 
(Kreilgaard, 2002). Later research concluded that MCM composed with GTCC at 1:1 
ratio effectively reduced the gel region, thus ME region was expanded and the 
particle size was decreased (Prajapati et al., 2012). This suggested that the MCM act 
as the co-surfactant with surfactant BRIJ O10 as it has an intermediate hydrophile-
lipophile balance (HLB) value. To further validate, the particle size of 
MCM/GTCC/BRIJ system should be measured. 
A complete dilution line within the ME region was identified in the phase diagram of 
the MCM: GTCC (1:1, w/w) /BRIJ system (Fig 3.4 (b)) and specific formulations 
along this line were used to evaluate the effect of MCM concentration on transdermal 
permeation rate. When these ME formulations were assessed for transdermal 
permeation using NaFlu, no correlation (R2 = 0.019) between MCM concentration 
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and Js was observed (Fig 3.6). The immiscible water and oil phase composed with 
the interfacial surfactant film can form distinct internal structure in the ME regions 
(Kreilgaard, 2002). This internal structure is significantly affected by the compounds 
formed, and the ratio between those compounds. In the dilution system of present 
study, the content change of MCM and other composition may alter the ME 
structures between oil-in-water structures, water-in-oil structures or bicontinuous 
structures. A variety studies has confirmed that the transdermal drug delivery of 
micro-emulsion is dependent not only on the its composition, but also on the internal 
structures (Kreilgaard et al., 2000, Podlogar et al., 2005). Therefore, the change of 
ME internal structure caused by the composition content alternative would be a 
reason that produces irregular Js between each formulation. To further evaluate, 
using the conductivity measurement and rheological methods would be help to 
characterize the ME phase inversion phenomena (Podlogar et al., 2004). 
In ME systems, short chain alcohols such as EtOH can act as a co-surfactant and 
further decrease the interfacial tension to produce larger areas of AT (Santos et al., 
2008). Therefore, EtOH was mixed with MCM in the ratio of 1: 1 (w/w) in the oil 
phase and pseudo-ternary phase diagrams were generated using water and a selection 
of different surfactants. A large AT (52.3%) was obtained in Fig 3.7 (a) comparing to 
the AT (33.2%) of Fig 3.4 (b), indicating that EtOH incorporated with MCM/BRIJ 
eliminated the gel region then particle size has been reduced and ME region was 
expanded (Prajapati et al., 2012). It is suggested that EtOH is acting as co-surfactant 
with surfactant BRIJ O10 as it has an intermediate HLB value. The particle size in 
this system may be worthwhile to measure in further studies. 
EtOH facilitates transdermal drug delivery as a solvent type enhancer (Barry, 1991). 
In the study of Morimoto et al. (1993), EtOH (40%) composed with 1-menthol 
exhibited synergistic transdermal permeation enhancement of morphine 
hydrochloride (2,467 g/cm2) when compared with EtOH applied alone (73 g/cm2). 
Significant permeation enhancement effect of ketotifen fumarate was also observed 
when EtOH incorporated with isopropyl myristate system (Nakamura et al., 1996). In 
this study, MCM/EtOH mixture significantly increased the Js of NaFlu in relative to 
MCM alone. Thus, we demonstrated that EtOH enhanced the transdermal permeation 
properties of MCM, for the first time. For the future studies, assessing different 
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concentrations of MCM and EtOH combinations would facilitate the development of 
more effective delivery formulations. 
To evaluate the effect of variable surfactants, different surfactants were combined 
with MCM-EtOH and corresponding transdermal permeation parameters were 
presented (Table 3.4). Permeation data presented the NaFlu Js produced by the 
MCM-EtOH combinations was significantly higher when compared to the rest 
MCM/EtOH based formulations (p < 0.05). The NaFlu Js produced by ME_T8 (732 
ng/cm2/h) similar (p > 0.05) to that produced by ME_BJ (846 ng/cm2/h), which were 
significantly higher (p < 0.05) than the NaFlu Js produced by both ME_CO (269 
ng/cm2/h) and ME_T2 (123 ng/cm2/h). Additional, the NaFlu Js produced by 
ME_CO was significantly higher (p < 0.05) than that produced by MCM_T2. Taken 
together, these data present different surfactant can have distinct influences on the 
transdermal permeation enhancing activity of MCM-EtOH combinations and suggest 
surfactant BRIJ O10, Kolliphor EL, Tween 20 and Tween 80 may act 
antagonistically with MCM-EtOH combinations. The different performance of 
ME_BJ, ME_CO, ME_T8 and ME_T2 may be the result of distinct interactions with 
the stratum corneum. It has been mentioned that colloidal structures of topical 
delivery formulations may influence the diffusion through the formulations and 
affect their permeation profile (Savić et al., 2009). Thus, it is necessary to further 
evaluate those formulations with polarization micrographs, conductivity measure and 
rheological test. Furthermore, to observe similar trend exist or not, other drug 
compounds would be tested.  
As the ME_BJ and ME_T8 formulations were found to be the most potent 
transdermal permeation enhancers, these formulations were further investigated for 
the transdermal delivery of the topical antibiotic, gentamicin. 
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4 DEVELOPMENT OF TOPICAL ME FORMULATIONS CONTAINING 
GENTAMICIN 
4.1 Introduction 
Skin and soft tissue infections (SSTIs) are the most common bacterial infections in 
humans and represent a large burden on global healthcare systems. SSTIs can be 
superficial, uncomplicated infections (including impetigo, erysipelas and cellulitis) 
or may be more severe, complicated infections involving deeper tissues which can 
require significant surgical intervention (including infected ulcers, major abscesses 
and necrotizing fasciitis). Additionally, recent evidence suggests that bacteria 
associated with many SSTIs (such as cutaneous abscesses and chronic wound ulcers) 
are present as highly persistent biofilm communities that are notoriously difficult to 
treat effectively due to the impermeable nature of these bacterial communities (James 
et al., 2008). 
Topical treatment of SSTIs represents the most direct approach for the delivery of 
antimicrobials to local sites of infection. Traditionally, topical antimicrobials are 
formulated as ointments/creams for direct application or are incorporated into wound 
dressings allowing controlled release at the wound surface. As traditional topical 
formulations display limited skin penetration of active antimicrobial compounds, 
topical treatment of SSTIs often produces incomplete bacterial eradication leading to 
increased rates of bacterial resistance (Lipsky and Hoey, 2009). Therefore, the 
development of more efficient and effective delivery mechanisms of topical 
antibiotic therapy for SSTIs is needed. 
In a recent study by Hess et al. (2014), gentamicin was shown to act synergistically 
with glycerol monolaurate to eliminate detectable viable biofilm bacteria.  Similarly, 
glycerol monocaprylate has also demonstrated synergistic anti-biofilm activity in 
combination with gentamicin against S. aureus biofilms (Proctor, 2015b).  Therefore, 
this part of the study focused on the development of topical ME formulations 
containing MCM C8 and gentamicin. 
4.2 Identification of suitable ME systems for gentamicin incorporation 
To optimise ME formulations containing gentamicin, solubility testing was 
conducted to ensure gentamicin was soluble at suitable concentrations in various ME 
systems. Gentamicin solubility was assessed in the MCM: GTCC (1: 1)/BRIJ 
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O10/water ME system shown in Fig 3.4. Gentamicin was not soluble at 10mg/mL in 
any of the specific formulations (ME_B to ME_F) along the minimum surfactant 
dilution line identified in Fig 3.4. Gentamicin was soluble in the MCM: EtOH (1: 
1)/Surfactant/water ME systems (Fig 3.7) at 10 mg/mL. 
4.3 Transdermal permeation kinetics of gentamicin from ME formulations 
 
Fig 4.1 Cumulative transdermal permeation of gentamicin through mouse skin over 
24 h after the application of ME formulation containing gentamicin. Formulations 
consisted of ME systems containing MCM/EtOH (1: 1, w/w) and either BRIJ O10 
(ME_BJ), Kolliphor EL (ME_CO) and Tween 80 (ME_T8) surfactants which 
contained 10 mg/mL gentamicin that was spiked with 0.5 Ci of tritium labeled [3H] 
gentamicin.  Each point represents means ± standard deviation of 3 to 4 biological 
replicates. (Appendix 7.23, 7.24, 7.25 and 7.26) 
ME formulations identified to be compatible with gentamicin (ME_BJ, ME_CO and 
ME_T8) were characterized for transdermal permeation. The composition of the 
formulations is shown in Table 4.1. All formulations contained 10 mg/mL of 
gentamicin and were spiked with 0.5 µCi of tritium labeled [3H] gentamicin to enable 
monitoring of transdermal permeation through mouse skin mounted in Franz 
diffusion cells. The transdermal permeation profile of gentamicin produced by these 
formulations is shown in Fig 4.1. From these graphs, the Js and accumulated amount 
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of gentamicin in the receptor chamber after 24-hour application (Q24h) were 
determined and presented in Table 4.1. 
Application of gentamicin dissolved in PBS produced a low Js of 525 ng/cm2/h 
indicating that gentamicin does not readily pass through full thickness mouse skin 
(Fig 4.1). By comparison to PBS, all ME formulations significantly enhanced the 
transdermal permeation of gentamicin through mouse skin (p<0.05). The Js produced 
by formulations ME_CO (7,633 ng/cm2/h) and ME_T8 (6,948 ng/cm2/h) were 
similar (p>0.05) while the Js produced by formulations ME_T8 (6,948 ng/cm2/h) and 
ME_BJ (5,350 ng/cm2/h) were similar (p>0.5). The Js produced by application of 
ME_CO was significantly higher (over 1.4-fold) than the Js produced by application 
of ME_BJ (p<0.05).  
Table 4.1 Permeation parameters of gentamicin (Js and Q24h) through full thickness 
mouse skin. All formulations contained 10 mg/mL gentamicin. 
Formulationa 
 
MCM 
(% w/w) 
EtOH 
(% w/w) 
Surfactant 
(% w/w) 
Water 
(% w/w) 
Js 
(ng/cm2/h) 
Q24h 
(ng/cm2) 
ME_BJ 
ME_CO 
ME_T8 
PBS 
10 
10 
10 
- 
10 
10 
10 
- 
20 
20 
20 
- 
60 
60 
60 
- 
5,350±251 
7,633±957 
6,948±1,960 
525±250 
81,464±10,701 
95,833±6,506 
81,378±18,375 
3,575±585 
4.4 Bio-distribution of gentamicin after topical application of a ME 
formulation 
Although formulation ME_CO presented higher Js and Q24h values, the 
MCM/EtOH/Kolliphor EL system was found to display limited stability when used 
to solubilise gentamicin. Therefore, the more stable, ME_T8 gentamicin formulation 
which effectively enhanced the transdermal permeation of this compound through 
full thickness mouse skin (see Fig 4.1), was further assessed in in vivo studies to 
determine the bio-distribution of gentamicin after topical application of the 
formulation to mice. In this study, gentamicin was dissolved in the ME formulation 
ME_T8 (Table 3.4), at 10 mg/mL gentamicin which was spiked with 0.5 µCi of 
tritium labeled [3H] gentamicin and topically applied on the shaved dorsal skin of 
mice. For the single dose (ME), the formulation was applied as a 10 µl aliquot on the 
right side of the dorsal region while the double dose (MEx2) was applied as two 
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separated 10 µl aliquots, one on each dorsal side. The negative control formulation 
consisted of 10 mg/mL gentamicin dissolved in PBS which was spiked with 0.5 µCi 
of tritium labelled [3H] gentamicin that was topically applied on the right side of the 
shaved dorsal skin of mice. The gentamicin amount in the mice tissue skin, muscle 
(underneath the site of skin collected), blood, small intestine, major lymph nodes 
(lumbar, axillary and brachial) and major clearance organs such as kidney, liver, 
spleen, lungs, and the wash buffer were measured.  
The results of wash buffer, skin, blood and kidney are showing below, the rest results 
are presented in the appendix (Appendix 7.27, 7.28, 7.29, 7.30, 7.31 and 7.32). 
In Fig 4.2 (a), at all time points except 3 h, the amount of gentamicin stay in the wash 
buffer was significantly higher after PBS treatment when compared to both ME 
treatment and MEx2 treatment (indicated with **, p < 0.05) while at 3 h that was 
significantly higher after PBS treatment comparing to the ME treatment (indicated 
with *, p < 0.05). At time 6h and 24 h, the amount of gentamicin accumulated in the 
MEx2 treatment was significantly higher than that accumulated in the ME treatment 
(indicated with ***, p < 0.05).  
In Fig 4.2 (a), the amount of gentamicin remains in the wash buffer after PBS 
treatment wasn’t significantly changed during 48 h (p>0.05) and it is significantly 
higher comparing to that of ME treatment at all time point (p<0.05). Those results 
suggested that the gentamicin of PBS treatment didn’t transdermal delivered into 
skin. It is evidence that the decrease trend can be observed in the wash buffer of 
MEx2 treatment, indicating the gentamicin was transdermal delivered into the skin. 
Similar trend should be observed in the ME treatment as well. Since the amount of 
gentamicin in the wash buffer after ME treatment was low and the its SEMs are 
relevant big, it didn’t show significant decrease trend in the static analysis.  
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Fig 4.2 The amount of gentamicin present in the skin buffer (a) and the amount of 
gentamicin accumulated in the skin tissue at the site of topical application (b) over 48 
hours post application. All formulations contained 10 mg/mL gentamicin that was 
spiked with 0.5 µCi of tritium labelled gentamicin and are described in Table 3.4. 
Each point represents a mean ± standard error of the mean (SEM) of 3 to 4 biological 
replicates.  
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In Fig 4.2 (b), at 3 h the amount of gentamicin in the skin was significantly lower 
after ME treatment when compared to the PBS treatment (indicated with *, p < 0.05). 
At 48 h, the amounts of gentamicin in the skin were significantly lower after the 
application of both ME and MEx2 when compared to the application of PBS 
treatment (indicated with **, p < 0.05). 
In Fig 4.2 (b), the amount of gentamicin accumulated in the skin after PBS treatment 
wasn’t significantly changed during 48 h (p>0.05). However, it is as high as the 
MEx2 treatment at the first 24 hours (p>0.05). If the gentamicin of PBS treatment 
didn’t penetrate through the skin, one possible reason here would be the gentamicin 
precipitation was hard to washed off, it adhered on the skin until the skin was 
dissolved in the Solvable and measured. In comparison, the gentamicin amount 
accumulated in the skin of MEx2 treatment presented a decrease trend between 3 h 
and 12 h (p<0.05), suggesting the gentamicin of MEx2 treatment was transdermal 
delivered through the skin. Similar trend supposed to be observed in the ME 
treatment as well as the MEx2 treatment. However, since its SEMs were big and 
amounts of gentamicin accumulated were low, it didn’t show such a trend in the 
static analysis. 
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Fig 4.3 The amount of gentamicin accumulated in the blood (a) and the kidney (b) 
over 48 hours post application. All formulations contained 10 mg/mL gentamicin 
that was spiked with 0.5 µCi of tritium labelled gentamicin and are described in 
Table 3.4. Each point represents a mean ± standard error of the mean (SEM) of 3 to 4 
biological replicates. 
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In Fig 4.2 (a), at 24 h and 48 h, the amount of gentamicin accumulated in the blood 
was significantly lower after ME treatment and MEx2 treatment (indicated with *, p 
< 0.05) when compared with that after PBS treatment. At 3 h and 24 h, the amount of 
gentamicin accumulated in blood was significantly higher after MEx2 treatment 
comparing to the ME treatment (indicated with **, p < 0.05). 
In Fig 4.3 (a), the amount of gentamicin accumulated in the blood was significantly 
higher when compared with that of ME treatment at 3 h, proving that the gentamicin 
was transdermal delivered into the blood after MEx2 treatment. There is a dramatic 
decrease trend (p<0.05) for gentamicin amount accumulated in the blood of MEx2 
treatment between 3 h and 12 h, indicating the gentamicin was take part in to the 
systemic circle after MEx2 treatment. There is no significant difference (p>0.05) of 
gentamicin amount accumulated in blood after both PBS and ME treatment over 24 
h.  
In Fig 4.2 (b), the gentamicin accumulated in the kidney after MEx2 treatment was 
significantly higher than that in both ME and PBS treatment at all time points (p < 
0.05). At 6 h, the gentamicin amount accumulated in the kidney of MEx2 treatment 
was significantly higher than that in the MEx2 treatment (indicated with *, p < 0.05). 
In Fig 4.3 (b) the gentamicin amount accumulated in the kidney after both ME and 
MEx2 treatment were significantly higher than that after PBS treatment. Taken 
together, above results suggested the amount of gentamicin was transdermal 
delivered into the blood and accumulated in the kidney via the systemic circle after 
ME and MEx2 treatment. The reason that no significant different was observed of 
gentamicin amount in the blood after ME treatment over 24 h may because it’s low 
amount of gentamicin and relative high SEM of ME treatment. However, since there 
is significantly lower rate of gentamicin accumulated in the kidney after PBS 
treatment comparing with that after ME and MEx2 treatment, suggesting that the 
gentamicin didn’t transdermal delivered through the skin and take part into the 
systemic circle. It is also noticed that the gentamicin amount accumulated in the 
kidney demonstrated an increase trend between 3 h and 6 h after ME treatment when 
compared with the decrease trend observed in the blood between 3 h and 6 h, 
suggesting that the gentamicin was accumulating in the kidney via the blood during 
this period. 
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4.5 Discussion 
Topical gentamicin preparations are commercially available and are used to treat 
minor skin infections (such as impetigo, folliculitis) or infections associated with 
other skin conditions (such as eczema, psoriasis, minor burns/cut/wound) (Zanca, 
1969). Topical gentamicin formulations are currently available as an ointment 
(Binenbaum et al., 2010), spray pack solution (Osawa et al., 2016) or a cream 
(AlShwaimi et al., 2016). However, previous study observed that the transdermal 
delivery of gentamicin from water-miscible bases was greater and faster than from 
ointment bases (Stone et al., 1968). Moreover, several former experiments proved 
that gel and ointment based topical formulations performed lower value than W/O 
emulsions or O/W emulsions in terms of transdermal drug delivery (Gomes et al., 
2004, Fini et al., 2008). These researches suggest that ME could be an interesting 
alternative to improve topical delivery of gentamicin. With recent studies 
demonstrating synergistic, anti-biofilm activity between MCM and gentamicin, ME 
formulations containing MCM and gentamicin were developed and characterised 
(Proctor, 2015a, Hess et al., 2014). 
Gentamicin was readily soluble in the MCM/EtOH based formulations and three 
gentamicin containing formulations (ME_BJ, ME_CO and ME_T8) were assessed 
for transdermal delivery (Table 4.1). The gentamicin Js produced by ME_BJ (5,350 
ng/cm2/h), ME_CO (7,633 ng/cm2/h) and ME_T8 (6,948 ng/cm2/h) were 
significantly higher when compared with that produced by PBS (525 ng/cm2/h). The 
gentamicin Js produced by ME_BJ reaching statistical difference in comparison with 
that produced by ME_CO. These data indicate that different surfactants can have 
different influence on the transdermal permeation enhancing activity of MCM-EtOH 
based formulations and suggest ME_BJ, ME_CO and ME_T8 has the potential to 
effectively transdermal deliver gentamicin. It is suggested that the colloidal 
structures of topical permeation formulations may affect the difference through the 
formulation and alter their permeation ability. Furthermore, it is observed that the 
performance of gentamicin Js was superior to the performance of NaFlu Js of 
formulation ME_CO. Savić et al. (2009) concluded that permeation performance of 
two different model drugs may principally affected by the vehicle/solute interaction. 
This suggests the transdermal permeation of small compounds can be influenced by 
specific interactions with surfactants present in ME formulations (Karande et al., 
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2007, Karande et al., 2004). To investigate, the nature of drug compounds such as 
partition coefficient within the formulation and its effect to permeation profile would 
be promising to verify in future studies. 
Tween 80 is widely used in a variety of drug formulation vehicles and as formulation 
ME_T8 produced high transdermal flux for gentamicin ex vivo, this formulation was 
assessed for in vivo transdermal delivery using mice (Hosmer et al., 2009, 
Watnasirichaikul et al., 2002, Constantinides et al., 1994). 
In the bio-distribution experiment performed, mice were topically treated with either 
PBS containing 10 mg/mL gentamicin, one dose of the ME containing 10 mg/mL or 
two identical doses of the ME containing 10 mg/mL. At each time point, the topical 
application site was washed to assess how much of the gentamicin in formulation 
remained on the surface of the skin. The amount of gentamicin present in the skin 
wash buffer from mice treated with PBS was high and remained relatively constant 
over the 48 hours post treatment.  The amount of gentamicin present in the skin wash 
buffer from mice treated with the ME formulations was consistently lower when 
compared to the PBS treated group and was also seen to decline overtime. Taken 
together, this suggests that when mice were topically treated with PBS, high 
quantities of gentamicin remained on the skin surface and when treated with ME, 
gentamicin permeated through the skin more readily. 
The profile of gentamicin accumulation in the skin after ME treatment suggests 
gentamicin rapidly permeated into deeper skin tissue. After this rapid accumulation 
post ME treatment, the concentration of gentamicin was then seen to slowly decline 
over time suggesting gentamicin could be spreading systemically. This is further 
supported by the gentamicin accumulation profile in kidney whereby after the ME 
treatment, gentamicin concentration increases in the first 12 h post application and 
then declines over the next 36 hours. 
The high amount of gentamicin seen in PBS treated skin may be the result of 
gentamicin penetration into skin or inefficient removal of gentamicin from skin 
surface by the wash method used. This could be investigated further by using 
stronger wash buffers (e.g. those containing higher concentrations of detergent or 
ethanol). The penetration of gentamicin into skin layers could be assessed more 
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accurately via strip taping striping which has been used to determine the depth and 
lateral spread of compounds through skin tissue. (Hahn et al., 2010, Gee et al., 2012). 
In the present study, mice treated with ME formulations were shown to accumulate 
gentamicin in the kidney. Those treated with PBS formulations did not. This 
indicates ME formulations were facilitating transdermal permeation of gentamicin 
producing systemic delivery.  This effect was found to be dose dependent as 
indicated by those mice in the MEx2 treatment group accumulating 2.3-fold more 
gentamicin in the kidney when compared to the single ME treatment at 6 h post 
application. In addition, the kidney concentration of gentamicin of MEx2 treatment 
reach the highest at 6 h while that of ME treatment reach the highest at 12 h. This 
suggests that the MEx2 treatment produces faster transdermal permeation when 
compared to the ME treatment. While the majority of drug compounds are excreted 
from the body via the kidney, gentamicin is known to cause nephrotoxicity as it 
binds to phospholipids within the membrane of the proximal tubule cell specific in 
the kidney (Smith et al., 1980). While this may be a potential problem for the topical 
gentamicin formulation produced in this project, the data presented in this thesis does 
indicate that ME formulations containing the transdermal permeation enhancer, 
monocaprylate, can facilitate systemic drug delivery after topical application. 
However, producing high systemic drug concentrations post topical application may 
have unwanted side effects if the compounds have known systemic toxicity 
properties Therefore, in future studies, it will be necessary to optimize the ME 
formulation to get good penetration through the skin but reduced systemic dose. The 
Js generated in this study would be optimized to produce better localized drug 
concentrations versus systemic concentrations (i.e. different drug concentration 
elaboration and dosing regimens, systemic concentration). Moreover, based on the 
equivalent surface area dosage conversion factors between animal and human 
(Rockville, 2005), the gentamicin dose applied in this study (6.67 and 13.34 mg/kg) 
would be optimized to use in the next set of in vivo experiments. Last but not least, 
the pharmacokinetics should be evaluated in vivo in the future study. For example, 
the process of antibiotics release from the ME based formulations and the removal of 
gentamicin from the body should be designed and evaluated.   
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5 CONCLUSIONS 
ME formulations have great potential for use as transdermal drug delivery vehicles 
due to their thermodynamic stability and spontaneous formation (Shakeel et al., 
2008). The composition and internal structure of ME can affect the internal mobility 
of the drugs in the vehicle, which influences the transdermal drug delivery 
performance of ME (Kreilgaard, 2002). MCM are approved for human use and have 
been incorporated into commercial formulations for decades (Paudel et al., 2010). 
MCM are known transdermal permeation enhancers and can be easily incorporated 
into ME formulations (Furuishi et al., 2007, Russell-Jones and Himes, 2011). 
Furthermore, MCM have broad spectrum antimicrobial properties including anti-
biofilm activity (Schlievert et al., 1992, Bergsson et al., 2001, Hess et al., 2014, 
Proctor, 2015a). Taken together, these properties of MCM make them highly 
attractive for use in more effective, topical antimicrobial formulations.  
The aim of this project was to utilize MCM in biocompatible ME formulations for 
transdermal drug delivery. The influence of medium chain mono and triglyceride 
concentration, non-ionic surfactants and co-surfactants on ME systems was 
characterized through the construction of pseudo-ternary phase diagrams and the 
transdermal permeation properties of selected formulations was assessed in vitro and 
in vivo. 
Present project demonstrated that formulation ME_A effectively enhanced the 
transdermal delivery rate of NaFlu through full thickness mouse skin. Further 
assessment revealed MCM act as the permeation enhancer in formulation ME_A 
while the presence of GTCC in the formulation ME_A decreased the transdermal 
permeation enhancing properties of MCM. When investigating the permeation 
profiles of variable surfactants incorporated with MCM, Surfactant BRIJ O10 
demonstrated synergistic effect on transdermal permeation delivery of NaFlu. It is 
proved that increasing MCM can expand the AT at a ratio to GTCC of 1: 1. 
Moreover, phase diagrams which established with MCM/EtOH and surfactants 
produced larger monophasic area in comparison with that of MCM/GTCC based 
formulations, suggesting EtOH is potent to form stable ME formulations. After 
evaluating the effect of different surfactants on the transdermal delivery profiles, 
permeation results presented that the NaFlu Js produced by formulation ME_T8 = 
ME_BJ > ME_CO > ME_T2. 
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Previous researches have shown that gentamicin acts synergistically with MCM to 
eradicate on S. aureus biofilm (Proctor, 2015b, Hess et al., 2014). Therefore, the 
incorporation of gentamicin into ME formulations was assessed. Results showed that 
formulation ME_T8, ME_CO and ME_BJ all effectively enhanced the transdermal 
delivery rate of gentamicin through full thickness mouse skin. ME_T8 was chosen to 
test the bio-distribution in vivo. The bio-distribution results showed that gentamicin 
accumulated in the kidney reaching statistical significance after application of 
formulation ME_T8 (both single dose and double dose groups) in comparison with 
the control group. This indicates that ME_T8 facilitated the transdermal delivery of 
gentamicin through mouse skin to produce detectable systemic drug levels. 
In conclusion, ME formulations composed by MCM and EtOH are favourable for the 
transdermal drug delivery. In future studies, it is recommended that characterizing 
ME formulations with conductivity measure, rheology test and polarization 
microscopy would be promising. What’s more, it is promising to examine variable 
antibiotic drugs incorporated with ME formulations.  
Overall, this set of topical ME formulations with enhanced permeation capacity for 
the antibiotics (gentamicin) were constructed and evaluated in mice body. Greater 
range of ME formulations were found to use as transdermal delivery vehicles in this 
article, indicating that optimized ME formulations have more potential to fulfil 
variable requirement. The permeation enhancement ability of ME formulations 
presented in this study, informing ME formulations have a great capacity to 
incorporate with antibiotic drugs to replace current commercial antibiotic 
cream/ointment/gel. 
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7 APPENDIX 
7.1 Materials and solutions 
 
Phasphate buffered salin (PBS) (1 x) 
 
NaCl          8 g/L 
KCl          0.2 g/L 
Na2HPO4         1.44 g/L 
KH2PO4         0.24 g/L 
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7.2 Specification Sheets 
Appendix 7.1 Certificate of analysis of Crodamol GTCC-LQ-(SG), listing the 
percentage breakdown of the oil components, indicating 57.8 caprylic and 42.2% 
capric triglycerides 
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Appendix 7.2 Certificate of analysis of Capmul MCM, listing the percentage 
breakdown of the oil components, indicating 58.4% MCM, glyceryl monocaprylate 
(C8) and glyceryl caprate (C10). 
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7.3 Transdermal delivery assay of NaFlu (MCM/GTCC based formulations) 
 
Appendix 7.3 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
 
Appendix 7.4 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.5 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.6 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological 
replicates.  
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Appendix 7.7 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.8 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.9 Cumulative transdermal delivery of NaFlu through mouse skin in vitro 
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in 
Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.10 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.11 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.12 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.13 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.14 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.15 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.16 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.17 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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7.4 Transdermal delivery assay of NaFlu (MCM/EtOH based formulations) 
 
Appendix 7.18 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.19 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.20 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
 
Appendix 7.21 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
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Appendix 7.22 Cumulative transdermal delivery of NaFlu through mouse skin in 
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described 
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological 
replicates. 
7.5 Transdermal delivery assay of gentamicin (MCM/EtOH based 
formulations) 
 
Appendix 7.23 Cumulative transdermal delivery of gentamicin through mouse skin 
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was 
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each 
point represents means ± standard deviation of 3 to 4 biological replicates. 
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Appendix 7.24 Cumulative transdermal delivery of gentamicin through mouse skin 
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was 
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each 
point represents means ± standard deviation of 3 to 4 biological replicates. 
 
Appendix 7.25 Cumulative transdermal delivery of gentamicin through mouse skin 
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was 
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each 
point represents means ± standard deviation of 3 to 4 biological replicates. 
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Appendix 7.26 Cumulative transdermal delivery of gentamicin through mouse skin 
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was 
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each 
point represents means ± standard deviation of 3 to 4 biological replicates. 
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7.6 Bio-distribution assay of gentamicin (MCM/EtOH based formulations) 
 
Appendix 7.27 Cumulative gentamicin amount in the spleen of mice in vivo over 48 
hours. All formulations contained 10 mg/mL gentamicin that was spiked with 0.5 
µCi tritium labelled gentamicin and are described in Table 3.4. Each point represents 
means ± standard error of the mean (SEM) of 3 to 4 biological replicates. At 24 h, 
the amount of gentamicin in spleen was significantly lower after ME treatment when 
compared to the PBS treatment (indicated with *, p < 0.05). 
 
Appendix 7.28 Cumulative gentamicin amount in the liver of mice in vivo over 48 
hours. All formulations contained 10 mg/mL gentamicin that was spiked with 0.5 
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µCi of tritium labelled gentamicin and are described in Table 3.4. Each point 
represents means ± standard error of the mean (SEM) of 3 to 4 biological replicates. 
At 12 h and 48 h, the amount of gentamicin in liver was significantly lower after ME 
treatment when compared to the MEx2 treatment (indicated with *, p < 0.05). 
 
Appendix 7.29 Cumulative gentamicin amount in the lung of mice in vivo over 48 
hours. All formulations contained 10 mg/mL gentamicin that was spiked with 0.5 
µCi of tritium labelled gentamicin and are described in Table 3.4. Each point 
represents means ± standard error of the mean (SEM) of 3 to 4 biological replicates. 
At 3 h, 6 h, 12 h and 24 h, the amount of gentamicin in lung was significantly lower 
after ME treatment when compared to the MEx2 treatment (indicated with *, p < 
0.05). 
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Appendix 7.30 Cumulative gentamicin amount in the small intestine of mice in vivo 
over 48 hours. All formulations contained 10 mg/mL gentamicin that was spiked 
with 0.5 µCi tritium labelled gentamicin and are described in Table 3.4. There is no 
significant different between each treatment group. Each point represents means ± 
standard error of the mean (SEM) of 3 to 4 biological replicates. 
 
Appendix 7.31 The transdermal permeation gentamicin amount accumulated in the 
underneath muscle at the site of topical application of mice in vivo over 48 hours. All 
formulations contained 10 mg/mL gentamicin that was spiked with specific amount 
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of tritium labelled gentamicin and are described in Table 3.4. Each point represents 
means ± standard error of the mean (SEM) of 3 to 4 biological replicates. At 6 h, the 
amount of gentamicin in the muscle was significantly lower after ME treatment when 
compared to the PBS and MEx2 treatment (indicated with *, p < 0.05). At 24 h, the 
amount of gentamicin in the muscle was significantly lower after ME treatment than 
that after PBS treatment group (indicated with **, p < 0.05). The gentamicin 
amounts in the muscle after both ME treatment and MEx2 treatment were 
significantly lower than the PBS treatment in the 48 h (indicated with ***, p < 0.05). 
 
Appendix 7.32 Cumulative gentamicin amount in the lymph nodes of mice in vivo 
over 48 hours. All formulations contained 10 mg/mL gentamicin that was spiked 
with 0.5 µCi of tritium labelled gentamicin and are described in Table 3.4. Each 
point represents means ± standard error of the mean (SEM) of 3 to 4 biological 
replicates. At 6 h, the amount of gentamicin in the lymph nodes was significantly 
lower after ME treatment when compared to the PBS treatment (indicated with *, p < 
0.05). 
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